乌鸦传媒

乌鸦传媒 spoke with experts during an Instagram Live 2 years ago about the growing buzz around GLP-1 receptor agonists and their role in transforming diabetes and obesity care. Since then, the use of medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has become even more widespread as the drugs' list of proven and potential benefits grow.

Recent research has suggested that GLP-1 agonists may offer benefits for people with alcohol, opioid, and tobacco use disorders, and shown associations between use of the drug class and a lower risk of Alzheimer's disease. Studies have also tied GLP-1 drugs to reduced risk of COVID-19 mortality, obesity-related cancers, and glaucoma in certain patients.

However, the drugs have their limits -- such as weight-loss plateaus and weight regain after stopping treatment -- and as their popularity grows, questions remain about perioperative and long-term safety, compounded drug risks, as well as equitable access and affordability.

In an upcoming Instagram Live, 乌鸦传媒 will revisit the conversation to discuss how the landscape has changed and what clinicians need to know about these revolutionary drugs -- join us!

Featuring:

Jeremy Faust, MD (moderator) editor-in-chief at 乌鸦传媒 ()

Karl Nadolsky, DO, clinical endocrinologist and obesity specialist at Holland Hospital ()

Fatima Cody Stanford, MD, MPH, MPA, MBA, associate professor of medicine and pediatrics at Massachusetts General Hospital and Harvard Medical School ()

How do I join? on Instagram!

When is the event? Tune in Monday, December 2 at 2 p.m. ET

Can I submit questions? Yes, we encourage questions! Submit your questions prior to the event by commenting below.

Related articles:

Ozempic Linked With Lower Risk of Alzheimer's Diagnosis

Here's How Compounders Make Popular Weight-Loss Drugs

Over 50% of U.S. Adults Qualify for Ozempic, Wegovy

FDA Adds New Warning to GLP-1 Drugs

GLP-1 Drugs Could Help People With Alcohol Use Disorder

GLP-1 Agent May Hold Opioid Use Disorder Benefit

The Data Are Clear: Patients Regain Weight After Stopping GLP-1 Drugs

GLP-1 Agonists May Offer Protection Against Glaucoma in Type 2 Diabetes

People Without Diabetes Make Up Growing Share of GLP-1 Users

Can a GLP-1 Agonist Improve Parkinson's Symptoms?

GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients

Wegovy Protects Against Deadly COVID Cases

How Often Do Doctors Use New Weight-Loss Drugs in Kids?

Comment